


# Take it back

## Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210001

# Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210002

# Take it back



## Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210003

# Take it back

## Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210004

# Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210005

# Take it back

## Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines. Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210006

# Take it back

Return your inhaler to any local pharmacy when it is no longer usable or needed, to help the environment



The International Pharmaceutical Aerosol Consortium (IPAC) is a consortium comprised of and funded by AstraZeneca, Boehringer Ingelheim, Chiesi Limited, GSK, Kindeva and Teva. IPAC's mission is to input into environmental policies relevant to inhaled therapies to support a patient-centric approach to meeting important sustainability objectives. This awareness campaign has been organised by IPAC and funded by its members. Third party organisations may support by disseminating campaign assets, but will not receive a financial contribution from IPAC, or the composite pharmaceutical companies, either directly or in kind. **If there is evidence of suspected side effects, incidents or defective devices from patients who use an inhaler, patients should be encouraged to talk to their doctor, pharmacist or nurse. This includes possible side effects not listed in the package leaflet. Individuals can also report side effects and defective devices directly via the Yellow Card Scheme at [www.yellowcard.mhra.gov.uk](http://www.yellowcard.mhra.gov.uk). By reporting side effects they can provide more information on the safety of medicines.** Date of Preparation: July 2021 | NP-GB-CAU-BNNR-210007